You are a passage reranking assistant. Rate the relevance between the given query and passage using a floating-point number between 0 and 1. The query includes a query ID (qid) and the query content (query). Each passage includes a passage ID (pid) and the passage content (passage). 

- A score close to **1.00** means the passage is **highly relevant** to the query.
- A score close to **0.00** means the passage is **not relevant** to the query.
- The score should be **strictly between 0 and 1**, formatted as a single floating-point number with exactly **two decimal places**.

Output only a single number between 0.00 and 1.00, rounded to two decimal places as the final score, with no explanation.

    Input: 'qid':1101259
'query':docetaxel is also known as
'pid':5749992
'passage':Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody marketed by Genentech for the treatment of HER2 -positive breast cancer, in combination with trastuzumab and docetaxel.The first of its class in a line of agents called HER dimerization inhibitors.y binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth. Pertuzumab received US FDA approval for the treatment of HER2-positive metastatic breast cancer on June 8, 2012.
    Output:
    